StockData

Lexicon Pharmaceuticals vs Sunshine Biopharma

LXRX and SBFM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LXRX and SBFM compare

Lexicon Pharmaceuticals is the larger company, worth 77 times as much as Sunshine Biopharma ($779M against $10.1M).

Sunshine Biopharma grew revenue faster over the last twelve months (−2.7% versus −29.0% for Lexicon Pharmaceuticals).

Sunshine Biopharma keeps more of each dollar of sales as profit, with a net margin of −16.5% compared with −147% at Lexicon Pharmaceuticals.

Sunshine Biopharma scores higher on the StockData Score (10 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLXRXSBFM
Size and price
Market cap$779M$10.1M
Share price$1.75$2.60
Change, 1 year21.5%−99.2%
Change, 5 years−63.1%−78.3%
Beta (5Y)0.03–
Employees8150
StockData Score
Total score510 (better)
Valuation score01 (better)
Growth score11
Performance score23 (better)
Health score25 (better)
Dividend score00
Valuation
P/S18.8×0.3× (better)
P/B4.5×0.4× (better)
FCF yield–−53.3%
Fair value$0.951–
Margin of safety−84.1%–
Growth
Revenue growth (TTM)−29.0%−2.7% (better)
Revenue growth, 5Y average15.7%248% (better)
Profitability
Gross margin99.1% (better)30.3%
Operating margin−131%−16.6% (better)
Net margin−147%−16.5% (better)
FCF margin–−15.2%
Return on equity−40.2%−21.9% (better)
Return on invested capital−163%−31.9% (better)
Financial health
Debt / equity0.29 (better)0.00
Current ratio13.37 (better)5.46
Altman Z-score−4.97−0.88 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions81.9%2.1%
Held by insiders–1.8%
Insider net buying, 12 months$2.8M–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.